Atezolizumab, a PD-L1 antibody, has also been approved by the FDA and the EMA as a single-agent treatment for patients with mNSCLC with high PD-L1 expression [20,126], having shown significant benefits in treating patients with NSCLC in clinical trial NCT02409342 (Table 1). The gene discussed is CD274; the disease is non-small cell lung carcinoma.